Monoclonal antibodies can generally be used to treat nephrotic syndrome. Application of anti-CD20 monoclonal antibody can inhibit B-cell proliferation and differentiation and reduce the number of B-cells, as well as the synthesis of autoantibodies, therefore reducing the immune damage to the kidney by immune complexes. Currently, monoclonal antibodies are recommended for the treatment of membranous nephropathy with risk of disease progression or failure to remit/relapse after treatment with other immunosuppressive agents, frequent relapsing or hormone-dependent nephrotic syndrome in children, frequent relapsing/hormone-dependent microscopic lesion nephropathy in adults, and glucocorticoid-sensitive focal segmental glomerulosclerosis in adults. In addition it has been shown that anti-CD20 monoclonal antibody can predict disease recurrence by reconstitution of B-cells after clearance of B-cells. However, many of the treatment options are still experimental and not applied on a large scale. If nephrotic syndrome is diagnosed, it is recommended to consult a regular hospital as early as possible for standardized treatment to reduce the adverse effects of the disease.